header logo image


Page 6«..5678..2030..»

Archive for the ‘Global News Feed’ Category

Bavarian Nordic to hold Capital Markets Days in February 2024

Sunday, November 26th, 2023

COPENHAGEN, Denmark, November 22, 2023 – Bavarian Nordic A/S (OMX: BAVA) will hold a series of capital markets days in February 2024 for investors and analysts across Europe and the U.S.

Read the original here:
Bavarian Nordic to hold Capital Markets Days in February 2024

Read More...

Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Sunday, November 26th, 2023

BRISBANE, Calif., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that Douglas Love, president and chief executive officer, will participate in a fireside chat during the 6th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29, 2023 at 2:10 p.m. ET in Miami.

Read more here:
Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Read More...

Junshi Biosciences Announces Lancet Infectious Diseases Publication of Results from the 2nd Phase 3 Study of VV116 for Treating COVID-19

Sunday, November 26th, 2023

SHANGHAI, China, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced a new publication in the Lancet Infectious Diseases. The paper presents final analysis results from a multicenter, double-blind, phase 3, randomized controlled study (NCT05582629) evaluating the efficacy and safety of VV116 (mindeudesivir hydrobromide tablets, product code: VV116/JT001) in patients with mild-to-moderate COVID-19. This study demonstrated that VV116 significantly reduced the time to sustained clinical symptom resolution compared to placebo, with no observed safety concerns.

View original post here:
Junshi Biosciences Announces Lancet Infectious Diseases Publication of Results from the 2nd Phase 3 Study of VV116 for Treating COVID-19

Read More...

Bright Green Announces Third Quarter 2023 Financial Update and Milestone Progress

Sunday, November 26th, 2023

Bright Green has achieved several key milestones throughout the Quarter advancing progress against its strategic plan.

Originally posted here:
Bright Green Announces Third Quarter 2023 Financial Update and Milestone Progress

Read More...

Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023

Sunday, November 26th, 2023

Geneva, Switzerland, November 23, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that that it will issue its Third Quarter 2023 Financial Results on November 29, 2023. Tim Dyer, CEO , Robert Lütjens, Head of Discovery – Biology and Mikhail Kalinichev, Head of Translational Science, will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CET (15:00 GMT / 10:00 EST / 07:00 PST) the same day.

Visit link:
Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023

Read More...

MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus

Sunday, November 26th, 2023

MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus

Read the original here:
MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus

Read More...

Curium Completes Patient Enrollment of Phase 3 ECLIPSE Trial Ahead of Schedule

Sunday, November 26th, 2023

ST. LOUIS, Nov. 23, 2023 (GLOBE NEWSWIRE) -- Curium, a global leader in nuclear medicine, announced today the successful completion of patient enrollment in the pivotal Phase 3 ECLIPSE trial.

Go here to read the rest:
Curium Completes Patient Enrollment of Phase 3 ECLIPSE Trial Ahead of Schedule

Read More...

Novo Nordisk invests more than 16 billion Danish kroner in expansion of production facilities in Chartres, France

Sunday, November 26th, 2023

Bagsværd, Denmark, 23 November 2023 – Novo Nordisk today announced the investment of more than 16 billion Danish kroner (2.1 billion euros) starting in 20231 to expand the existing production site in Chartres, France, for the current and future product portfolio within serious chronic diseases.

Read more:
Novo Nordisk invests more than 16 billion Danish kroner in expansion of production facilities in Chartres, France

Read More...

Sanofi: Information concerning the total number of voting rights and shares – October 2023

Sunday, November 26th, 2023

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)

See the article here:
Sanofi: Information concerning the total number of voting rights and shares - October 2023

Read More...

Sosei Heptares to Regain Full Ownership of GSK4381406*, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease

Sunday, November 26th, 2023

Tokyo, Japan and Cambridge, UK, 24 November 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) announces it has initiated discussions with GSK to regain full ownership of GSK4381406, a highly selective first-in-class, oral GPR35 agonist in development under a Global Collaboration and License Agreement with GSK as a potential new treatment for Inflammatory Bowel Diseases (IBD). GPR35 is an important orphan G protein-coupled receptor (“GPCR”) with an established genetic association to IBD, for which there remains significant unmet need for millions of sufferers worldwide.

More here:
Sosei Heptares to Regain Full Ownership of GSK4381406*, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease

Read More...

Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation Award

Sunday, November 26th, 2023

Honor awarded last night recognizes Theratechnologies and Prof. Borhane Annabi for advancing preclinical development of sudocetaxel zendusortide for treatment of triple-negative breast cancer Honor awarded last night recognizes Theratechnologies and Prof. Borhane Annabi for advancing preclinical development of sudocetaxel zendusortide for treatment of triple-negative breast cancer

View original post here:
Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation Award

Read More...

Er-Kim Pharmaceuticals Supports Worldwide Prevention of Antimicrobial Resistance (AMR)

Sunday, November 26th, 2023

World AMR Awareness Week campaign looks to provide understanding of AMR and to promote best practices among all industry stakeholders to reduce the spread of drug-resistant infections World AMR Awareness Week campaign looks to provide understanding of AMR and to promote best practices among all industry stakeholders to reduce the spread of drug-resistant infections

Follow this link:
Er-Kim Pharmaceuticals Supports Worldwide Prevention of Antimicrobial Resistance (AMR)

Read More...

Compass Pathways to participate in upcoming Evercore investor conference

Sunday, November 26th, 2023

LONDON, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will hold a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference at 10:25 am ET on November 30, 2023.

More:
Compass Pathways to participate in upcoming Evercore investor conference

Read More...

NurExone Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Sunday, November 26th, 2023

TORONTO and HAIFA, Israel, Nov. 24, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a pioneering biotechnology company, released a corporate update and reported financial results for the quarter ended September 30, 2023.

View post:
NurExone Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Read More...

Humacyte to Present at the Piper Sandler 35th Annual Healthcare Conference

Sunday, November 26th, 2023

DURHAM, N.C., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, and Dale Sander, Chief Financial Officer, will present at the Piper Sandler 35th Annual Healthcare Conference, in New York, NY on November 30, 2023. Management will also be available for one-on-one meetings.

More here:
Humacyte to Present at the Piper Sandler 35th Annual Healthcare Conference

Read More...

New Hope for Children: SciSparc’s patented CBD- Enhanced Solution for Autism Spectrum Disorder

Sunday, November 26th, 2023

TEL AVIV, Israel, Nov. 24, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare disease of the central nervous system, has initiated a clinical trial using its proprietary therapy, SCI-210, at Soroka Medical Center, Israel, targeting Autism Spectrum Disorder (ASD) symptoms in children.

Link:
New Hope for Children: SciSparc's patented CBD- Enhanced Solution for Autism Spectrum Disorder

Read More...

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Sunday, November 26th, 2023

FLORHAM PARK, N.J., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a biotechnology company developing allogeneic cell therapies and biomaterial products, announced today that on November 21, 2023, the Company received notification from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance with Nasdaq’s continued listing requirements of the Company’s failure to timely file a Form 10-Q for the third quarter of 2023.

Read more from the original source:
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Read More...

Abeona Therapeutics Announces New Preclinical Data from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene &…

Wednesday, May 17th, 2023

Animal proof-of-concept for AAV-based gene therapies for Stargardt disease, X-linked retinoschisis and autosomal dominant optic atrophy Animal proof-of-concept for AAV-based gene therapies for Stargardt disease, X-linked retinoschisis and autosomal dominant optic atrophy

The rest is here:
Abeona Therapeutics Announces New Preclinical Data from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene &...

Read More...

ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders

Wednesday, May 17th, 2023

PORTLAND, Maine, May 16, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that its 2023 Annual Meeting of Stockholders will be conducted virtually.

Follow this link:
ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders

Read More...

PharmAla Biotech and Shaman Pharma Granted First Ever Special Access Program Authorization for MDMA

Wednesday, May 17th, 2023

This authorization is the first authorized treatment of a patient with MDMA outside of a clinical trial in Canadian history This authorization is the first authorized treatment of a patient with MDMA outside of a clinical trial in Canadian history

Originally posted here:
PharmAla Biotech and Shaman Pharma Granted First Ever Special Access Program Authorization for MDMA

Read More...

Page 6«..5678..2030..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick